Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Capital Leases (2018 - 2022)

Historic Capital Leases for BioNexus Gene Lab (BGLC) over the last 5 years, with Q1 2022 value amounting to $13021.0.

  • BioNexus Gene Lab's Capital Leases fell 5501.93% to $13021.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $13021.0, marking a year-over-year decrease of 5501.93%. This contributed to the annual value of $12803.0 for FY2021, which is 6372.27% down from last year.
  • As of Q1 2022, BioNexus Gene Lab's Capital Leases stood at $13021.0, which was down 5501.93% from $12803.0 recorded in Q4 2021.
  • BioNexus Gene Lab's Capital Leases' 5-year high stood at $62935.0 during Q4 2018, with a 5-year trough of $12803.0 in Q4 2021.
  • In the last 5 years, BioNexus Gene Lab's Capital Leases had a median value of $38169.0 in 2020 and averaged $35673.2.
  • In the last 5 years, BioNexus Gene Lab's Capital Leases tumbled by 1954.21% in 2020 and then plummeted by 6372.27% in 2021.
  • Over the past 5 years, BioNexus Gene Lab's Capital Leases (Quarter) stood at $62935.0 in 2018, then decreased by 28.36% to $45086.0 in 2019, then decreased by 21.72% to $35292.0 in 2020, then plummeted by 63.72% to $12803.0 in 2021, then rose by 1.7% to $13021.0 in 2022.
  • Its Capital Leases stands at $13021.0 for Q1 2022, versus $12803.0 for Q4 2021 and $18103.0 for Q3 2021.